Ischemic cardiomyopathy accounts for approximately 50% of patients with heart failure and one-third of the patients undergoing coronary artery bypass surgery.
Results | Of the 1000 surgical ventricular reconstructioneligible patients, 340 had baseline CMR studies and 660 did not; both groups were similar except for a slightly higher prevalence of renal insufficiency in those who did not have a CMR study (Table) . The mean (SD) age of the CMR group was 60.9 (9.8) years, the mean (SD) LVEF was 28% (11%), the mean (SD) Based on Kaplan-Meier estimates, at 4 years, there were 102 deaths (28%). The Figure shows the survival curves of patients divided into tertiles of LVEF and volume indices. There was a graded increase in mortality in patients with lower EFs. Similarly, mortality was higher in patients with larger LV volume indices.
We created multivariable models of survival outcomes adjusting for the effects of clinical and pharmacological variables and treatment assignment (age; sex; hypertension; diabetes; smoking; stroke; peripheral vascular disease; renal insufficiency; β-blocker, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, statin, and aspirin use; and assignment to surgical ventricular reconstruction or no surgical ventricular reconstruction groups). Adjusted for these Letters variables, CMR EF was a strong predictor of survival (Wald χ 2 , 11.9; hazard ratio, 0.84 per 5%; 95% CI, 0.76-0.93; P < .001). Left ventricular end-diastolic volume index (hazard ratio, 1.11 per 10 mL/m 2 ; 95% CI, 1.05-1.17; P < .001) and LVESVI (hazard ratio, 1.12 per 10 mL/m 2 ; 95% CI, 1.05-1.19; P < .001) were incrementally predictive of outcomes when added individually to the model including CMR EF.
Mortality over 4 years of follow-up was 19% in those with CMR EFs greater than 30%, 34% in those with EFs of 20% to 30%, and 33% in those with an EF less than 20%. Adding CMR LVESVI to EF improved the discriminating power of CMR analysis. The 4-year mortality rates were 0% in those with an EF greater than 30% and ESVI less than 30 mL/m 2 , as well as 37% in those with an EF less than 20% and ESVI greater than 80 mL/m 2 .
Discussion | This study adds many insights into the diagnostic evaluation of patients with ischemic cardiomyopathy. Data quality is high in this prospectively studied population within the STICH clinical trial environment. This study demonstrates that the combination of CMR-determined LVEF with ESVI provides good annual mortality risk.
To our knowledge, the present study provides the largest population of patients with ischemic cardiomyopathy that has used CMR to predict surgical outcomes. In the Digitalis Investigation Group Trial, a diminishing EF was associated with an increase in mortality in a graded fashion. However, it has been suggested in other studies that there may be an inflection point at approximately 25% below which there is no apparent further reduction in mortality. 5, 6 Using CMR-determined LVEF in combination with LVESVI allows improvement in risk stratification in patients with severe LV dysfunction.
